FDCDDQ
CADL icon

Federation des caisses Desjardins du Quebec’s Candel Therapeutics CADL Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$2.53K – 2903
2025
Q2 		$2.53K Sell
500
-2,500
-83% -$12.9K ﹤0.01% 2378
2025
Q1 		$16.9K Buy
3,000
+2,000
+200% +$16.3K ﹤0.01% 1780
2024
Q4 		$8.68K Buy
+1,000
New +$5.91K ﹤0.01% 1922

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's CADL Position: Q3 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Candel Therapeutics (CADL) in Q3 2025, closing a stake of 500 shares — an estimated $2.53K sold.

Federation des caisses Desjardins du Quebec first reported a position in CADL in Q4 2024 and held it in 3 quarters. The position peaked at $16.9K in Q1 2025. 81 funds tracked by Wall St. Rank hold CADL as of Q3 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining Candel Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 500 Candel Therapeutics shares in Q3 2025, an estimated $2.53K.
  • Federation des caisses Desjardins du Quebec first reported a position in Candel Therapeutics in Q4 2024 and held it in 3 quarters.
  • Federation des caisses Desjardins du Quebec's Candel Therapeutics position peaked at $16.9K in Q1 2025.
  • 81 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q3 2025, filed 14 Nov 2025.